The Prognostic Significance of Combined Pretreatment Fibrinogen and Neutrophil-Lymphocyte Ratio in Various Cancers: A Systematic Review and Meta-Analysis

Table 1

The basic information of included studies.

Study (year)	Tumor type	Region	No. of patients	Age (mean year)	Cancer stage or grade	Definition of F-NLR score	End point	Quality score
Arigami et al. (2015)	ESCC	Japan	238	65	Stage I-III	&; or; and	OS	7
Arigami et al. (2016a)	GC	Japan	275	66	Stage I-IV	&; or; and	OS	7
Arigami et al. (2016b)	GC	Japan	68	66	NR	&; or; and	OS	6
Fu et al. (2017)	HCC	China	130	49.5	NR	&; or; and	OS, DFS	6
Hao et al. (2019)	Glioblastoma	China	187	55	NR	&; or; and	OS	7
Huang et al. (2018)	NSCLC	China	589	60	Stage I-IIIA	&; or; and	OS, DFS	7
Kijima et al. (2017)	ESCC	Japan	98	64.9	Stage III-IV	&; or; and	OS	7
Kuwahara et al. (2018)	HPC	Japan	111	67	Stage III-IV	&; or; and	OS, PFS	7
Li et al. (2018)	CRC	China	693	NR	Stage I-III	&; or; and	OS, DFS	6
Liang et al. (2019)	NSCLC	China	456	61	Stage I-IIIA	&; or; and	OS	6
Liu et al. (2018)	GC	China	1293	59	Stage I-III	&; or; and	OS	7
Marchetti et al. (2018)	OC	Italy	94	55	Stage I-IV	&; or; and	PFS	6
Wang et al. (2018)	NSCLC	China	515	60.4	Stage I-IIIA	&; or; and	OS, DFS	7

ESCC: esophageal squamous cell carcinoma; GC: gastric cancer; HCC: hepatocellular carcinoma; NSCLC: non-small-cell lung cancer; HPC: hypopharyngeal carcinoma; CRC: colorectal adenocarcinoma; OC: ovarian cancer; OS: overall survival; DFS: disease-free survival; PFS: progression-free survival; multivariate analysis.